GM1 gangliosidosis is due to beta-galactosidase deficiency. Only patients with type 3 disease survive into adulthood and develop movement disorders. Clinical descriptions of this form are rare, particularly in non-Japanese patients. We describe four new patients and systematically analyze all previous reports found by a literature search and contacts with the authors for additional information. Generalized dystonia remained the predominant feature throughout the disease course and was often associated with akinetic-rigid parkinsonism. GM1 gangliosidosis must be considered as a cause of early-onset generalized dystonia, particularly in patients with short stature and skeletal dysplasia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.20593 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential Disease-Modifying Effects of Ganglioside GM1 Pulse Treatment on Spinocerebellar Ataxia Type 3, a Parallel-Group, Double-Blind, Randomized, Controlled Trial.
Mov Disord
January 2025
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Article Synopsis
- * This study investigated the effects of high-dose ganglioside GM1 on SCA3 patients by comparing it with low-dose GM1 and a placebo over 12 weeks, assessing changes in ataxia symptoms and safety.
- * Results showed that high-dose GM1 significantly improved motor function and daily living activities in patients, and all treatment groups were safe and well-tolerated.
Gangliosides in neural stem cell fate determination and nerve cell specification--preparation and administration.
bioRxiv
June 2024
Department of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta 30912, Georgia, USA.
Gangliosides are sialylated glycosphingolipids with essential but enigmatic functions in healthy and disease brains. GD3 is the predominant species in neural stem cells (NSCs) and GD3-synthase (sialyltransferase II; ) knockout (GD3S-KO) revealed reduction of postnatal NSC pools with severe behavioral deficits including cognitive impairment, depression-like phenotypes, and olfactory dysfunction. Exogenous administration of GD3 significantly restored the NSC pools and enhanced the stemness of NSCs with multipotency and self-renewal, followed by restored neuronal functions.
View Article and Find Full Text PDFEffect of GM1 concentration change on plasma membrane: molecular dynamics simulation and analysis.
Phys Chem Chem Phys
April 2024
School of Physics and Electronics, Shandong Normal University, Jinan, 250014, People's Republic of China.
Ganglioside GM1 is a class of glycolipids predominantly located in the nervous system. Comprising a ceramide anchor and an oligosaccharide chain containing sialic acid, GM1 plays a pivotal role in various cellular processes, including signal transduction, cell adhesion, and membrane organization. Moreover, GM1 has been implicated in the pathogenesis of several neurological disorders, such as Parkinson's disease, Alzheimer's disease, and stroke.
View Article and Find Full Text PDFAlpha-Synuclein and GM1 Ganglioside Co-Localize in Neuronal Cytosol Leading to Inverse Interaction-Relevance to Parkinson's Disease.
Int J Mol Sci
March 2024
Department of Pharmacology Physiology & Neuroscience, Rutgers, The State University of New Jersey, Newark, NJ 07103, USA.
Research on GM1 ganglioside and its neuroprotective role in Parkinson's disease (PD), particularly in mitigating the aggregation of α-Synuclein (aSyn), is well established across various model organisms. This essential molecule, GM1, is intimately linked to preventing aSyn aggregation, and its deficiency is believed to play a key role in the initiation of PD. In our current study, we attempted to shed light on the cytosolic interactions between GM1 and aSyn based on previous reports demonstrating gangliosides and monomeric aSyn to be present in neuronal cytosol.
View Article and Find Full Text PDFProduction and characterization of a chimeric protein targeting synuclein epitopes for immunotherapy against synucleinopathies.
Biotechnol Prog
January 2024
Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico.
The aggregation and spread of alpha-synuclein (αSyn) is associated with several pathogenic pathways that lead to neurodegeneration and, ultimately, to synucleinopathies development. Hence, the establishment of a safe and effective disease-modifying therapy that limits or prevents the spread of toxic αSyn aggregation could lead to positive clinical outcomes. A rational vaccine design can be focused on the selection of specific epitopes able to induce the immune response desired, for example, antibodies able to mediate the clearance of αSyn aggregates without the induction of inflammatory responses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!